Tag: RAP

ResApp Health TGA approval Australia smartphone respiratory diagnostic technology adults

ResApp Health locks-in Australian TGA approval for smartphone respiratory diagnostic technology in adults

ResApp Health (ASX: RAP) has finally locked-in Australian Therapeutic Goods Administration for using its smartphone-based diagnostic technology to determine respiratory disease in adults. This latest...
ResApp Health ASX RAP respiratory diagnostic test integrated Australian telehealth platform Coviu

ResApp Health’s respiratory diagnostic test to be integrated into Australian telehealth platform

ResApp Health (ASX: RAP) has entered an agreement to have its acute respiratory diagnostic test integrated into Australia’s leading telehealth software platform Coviu. According to...
ResApp ASX RAP respiratory disease TGA approval paediatric treatments

ResApp to take part in German digital health program, secures TGA approval

Digital health company ResApp Health (ASX: RAP) has been given an operational boost by a German health program backed by pharmaceutical giants Roche and Sanofi, while...
ResApp Health ASX RAP positive results obstructive sleep apnoea study at home

ResApp Health receives positive results from at-home sleep apnoea study

Digital health company ResApp Health (ASX: RAP) has updated the market with positive top-line results from its prospective, blinded at-home obstructive sleep apnoea study that...
ResApp ASX RAP CE Mark approval smartphone diagnostic test adult paediatric respiratory disease

ResApp Health can now market respiratory diagnostic technology for adults in EU

ResApp Health (ASX: RAP) has received Europe’s CE Mark approval for its latest smartphone-based respiratory disease diagnostic test for adults and children, paving the...
ResApp Health ASX RAP repiratory disease CE Mark EU

ResApp gets all-clear to market respiratory disease test in Europe

Digital health innovator ResApp Health (ASX: RAP) has received a significant boost courtesy of European regulatory approval for its first commercial product, ResAppDx-EU. The smartphone...
ResApp ASX RAP smartphone app lower respiratory tract diseases COPD asthma pneumonia

ResApp Health bounces back with ‘positive top-line results’ in adult respiratory disease study

ResApp Health (ASX: RAP) has reported “positive top-line results” from an adult clinical study, with the company’s smartphone app able to accurately diagnose all...
ResApp ASX RAP results Australian Prospective Paediatric Clinical Study breathe easy

ResApp continues its march towards improving detection of respiratory disease

Digital health company ResApp Health (ASX: RAP) is a step closer to making history and developing a clinically-proven means of detecting a swathe of respiratory diseases...
Lockheed Martin ResApp Health ASX RAP Warfighter Analytics using Smartphones Health WASH DARPA

Lockheed Martin partners with ResApp Health to predict warfighter readiness

Digital health company ResApp Health (ASX: RAP) has honed in on a relationship with Lockheed Martin, as part of the Defense Advanced Research Projects Agency (DARPA)...
ResApp Health ASX RAP ResAppDx technology SMARTCOUGH-C-2 study acute respiratory disease children

ResApp Health completes enrolment for acute respiratory disease study

Digital health company ResApp Health (ASX: RAP) is a step closer to clinically proving the capabilities of its proprietary ResAppDx app after announcing the...
ResApp Health ASX RAP sleep apnoea respiratory disease

ResApp achieves positive preliminary results in sleep apnoea study, respiratory disease research advances

ResApp Health (ASX: RAP) has achieved “excellent” preliminary results in its obstructive sleep apnoea trial using its smartphone application. The company is carrying out clinical...
ResApp Health ASX RAP diagnosing respiratory illness study algorithms smartphone app

ResApp achieves positive results in study diagnosing respiratory illnesses using algorithms

Digital healthcare provider ResApp Health (ASX: RAP) has achieved further positive results in its Australian adult clinical study for diagnosing respiratory illnesses using its...
ResApp Health RAP ASX enrolment SMARTCOUGH-C study

ResApp Health completes enrolment in SMARTCOUGH-C study

ResApp Health (ASX: RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, announced that it has...